ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO287

Pruritus in Patients With ESKD on Hemodialysis: Initial Results From a Prospective Patient Survey Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Thompson, Jeffrey, Cerner Enviza, North Kansas City, Missouri, United States
  • Kammerer, Jennifer A., Vifor Pharma Ltd., Redwood City, California, United States
  • Oliveira, Juliana H., Vifor Pharma Ltd., Redwood City, California, United States
  • Ashka, Lauren Leigh, Cerner Enviza, North Kansas City, Missouri, United States
  • Johansen, Kirsten L., Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
  • Yosipovitch, Gil, University of Miami School of Medicine, Miami, Florida, United States

Chronic kidney disease-associated pruritus (CKD-aP) is common in patients on hemodialysis (HD). Real-world assessment of the patient’s perspective of pruritis is needed. A US-based patient survey assessed treatment, and the humanistic and economic burden of CKD-aP.


Eligible participants were ≥18 years old with healthcare provider (HCP) diagnosed ESKD on 3 times/week HD. They self-reported itch assessed on a modified 28-day recall period using the worst itch numerical rating scale (WI-NRS; 0=no itch to 10=worst itch), from which they were stratified into mild (1–3), moderate (4–6), and severe (7–10) cohorts. Sleep quality was assessed on a 0–10 scale (10=itch completely interfered with sleep in the past 24 hours).


Of 299 completed surveys (2/3 planned population) from December 2021 to May 2022: 50, 126, and 123 were stratified into mild, moderate, and severe itch cohorts, respectively. Overall participants were 53% female, 53% white/non-Hispanic, 43% on Medicare plans, and 70% on in-center HD. Proportions of patients who had discussed chronic itch with an HCP, were diagnosed with CKD-aP, received HCP-recommended treatment, or were currently taking itch treatment increased with itch severity (Figure). Greater itch severity was associated with high/extremely high self-reported itch burden (mild=4.0%, moderate=26.2%, severe=39.8%), and sleep disruption (mild=2.3, moderate=4.6, and severe=6.4). Topical treatment was ubiquitous in all cohorts (100%) while systemic treatment was limited even in moderate to severe itch cohorts (24–40%).


More severe itch scores were associated with a greater likelihood of patient–HCP engagement about itch and related treatment, and poorer sleep quality. A gap in addressing itch is suggested by a lower rate of HCP-recommended treatment (57%) or HCP-diagnosed CKD-aP (56%) vs patients reporting itch to HCPs (69%), and limited use of systemic treatment in moderate to severe itch cohorts.


  • Commercial Support